Bio-Techne Corporation (TECH)’s Financial Results Comparing With G1 Therapeutics Inc. (NASDAQ:GTHX)

Both Bio-Techne Corporation (NASDAQ:TECH) and G1 Therapeutics Inc. (NASDAQ:GTHX) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bio-Techne Corporation 702.60M 11.23 121.21M 3.10 63.51
G1 Therapeutics Inc. N/A 0.00 88.83M -2.57 0.00

Demonstrates Bio-Techne Corporation and G1 Therapeutics Inc. earnings per share, gross revenue and valuation.


Table 2 provides Bio-Techne Corporation and G1 Therapeutics Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Bio-Techne Corporation 17.25% 11% 6.8%
G1 Therapeutics Inc. 0.00% -28.3% -27.2%


Bio-Techne Corporation has a Current Ratio of 4.3 and a Quick Ratio of 3.4. Competitively, G1 Therapeutics Inc.’s Current Ratio is 30.2 and has 30.2 Quick Ratio. G1 Therapeutics Inc.’s better ability to pay short and long-term obligations than Bio-Techne Corporation.


Bio-Techne Corporation pays out a $1.28 per share dividend on a yearly basis and it also offers 0.61% dividend yield. G1 Therapeutics Inc. does not offer a dividend.

Analyst Recommendations

Bio-Techne Corporation and G1 Therapeutics Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Bio-Techne Corporation 0 0 2 3.00
G1 Therapeutics Inc. 0 0 0 0.00

$205 is Bio-Techne Corporation’s average price target while its potential downside is -1.60%.

Institutional and Insider Ownership

Institutional investors held 95% of Bio-Techne Corporation shares and 86.5% of G1 Therapeutics Inc. shares. 0.38% are Bio-Techne Corporation’s share held by insiders. Comparatively, G1 Therapeutics Inc. has 0.5% of it’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Bio-Techne Corporation -2.6% -1.96% 4.04% 15.15% 29.42% 35.9%
G1 Therapeutics Inc. 13.68% 35.75% 12.76% -47.95% -49.4% 24.13%

For the past year Bio-Techne Corporation’s stock price has bigger growth than G1 Therapeutics Inc.


On 11 of the 12 factors Bio-Techne Corporation beats G1 Therapeutics Inc.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, including cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment develops, manufactures, and sells tools, such as Biologics platform that enables researchers interrogate protein purity and identify contaminants during the development and production of biologics; Simple Western platform for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment offers controls and calibrators for hematology clinical instruments; blood chemistry and blood gas quality controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market; bulk purified proteins, enzymes, disease-state plasmas, infectious disease antigens, and processed serums to the clinical diagnostic industry; and Paratest, a novel and convenient stool collection and test device for the veterinary market. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel therapeutics for the treatment of cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/IIa clinical trials for patients with small cell lung cancer, as well as Phase II clinical trial for patients with triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase I/II clinical trial for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader that is in preclinical development stage. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.